Clinical trial
Open access
Sep 2026
Long-term outcomes of eltrombopag plus cyclosporine A in eltrombopag-exposed patients with glucocorticoid-resistant or -dependent primary immune thrombocytopenia: a prospective, multicenter, single-arm, phase II study with extended follow-up
Background Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by thrombocytopenia, and approximately 20-30% of patients are refractory to or dependent on first-line glucocorticoid therapy. Our previous prospective phase II study demonstrated promising short-term efficacy of eltrombopag (ELT)...
Yu-Hui Yuan, Jie Jin, J. Lai et al.
· Frontiers in Immunology · 0 citations